Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More Insulin Innovation To Come, Says Novo CEO Sorensen

This article was originally published in The Pink Sheet Daily

Executive Summary

Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices


Related Content

Degludec Advisory Committee Is Another De Facto Delay For Novo
New Long-Acting Insulin Offerings Could Derail Lantus Franchise
Novo Nordisk Brings Renewed Education Efforts, But Not New Products, To Japan In 2012
Life Without Plavix: Sanofi Highlights Next Generation Drugs
Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation
Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
Pricing Under The Spotlight As Novo Files Next-Generation Insulins
Sanofi Delay Boosts Novo's Bid For Insulin Dominance
Novo Nordisk Toughens Long-Term Financial Targets As 2010 Sales Grew By 13%, Profits By 16%
Novo Highlights Degludec's Advantage Versus Lantus In Fewer Night-Time Hypoglycemic Events


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts